Stocktoria
NEKTAR THERAPEUTICS NKTR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1994-05-03
NEKTAR THERAPEUTICS financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M |
| R&D expense | $117.3M | $120.9M | $114.2M | $218.3M | $400.3M |
| Operating income | -$140.1M | -$105.2M | -$263.7M | -$376.2M | -$446.1M |
| Interest expense | — | — | — | $0 | $0 |
| Income tax | -$138,000 | -$239,000 | -$200,000 | $3.2M | $557,000 |
| Net income | -$164.1M | -$119.0M | -$276.1M | -$368.2M | -$523.8M |
| EPS (diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
| Operating cash flow | -$208.5M | -$175.7M | -$192.6M | -$304.0M | -$412.7M |
| Free cash flow | -$208.7M | -$177.2M | -$193.5M | -$309.7M | -$427.6M |
| Cash & equivalents | $15.1M | $44.3M | $35.3M | $88.2M | $25.2M |
| Inventory | $0 | $0 | $16.1M | $19.2M | $15.8M |
| Total assets | $280.4M | $303.9M | $398.0M | $710.6M | $1.1B |
| Total liabilities | $190.6M | $243.1M | $267.0M | $344.0M | $437.7M |
| Shareholders' equity | $89.8M | $60.7M | $131.0M | $366.6M | $679.5M |
Source: SEC EDGAR filings · CIK 0000906709 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.